Rothenberg Lab
Current Projects

Immunopathogenesis of Allergic Inflammation

An objective of Dr. Marc Rothenberg’s research program is to elucidate the cellular and molecular processes involved in allergic responses in the gastrointestinal tract and lung. His laboratory has developed unique antigen-induced and genetically engineered in vivo murine, and translational human ex vivo model systems, enabling him to identify key checkpoints that regulate Th2 immunity. Findings from this research have identified and elucidated the role of IL-5, the eotaxin subfamily of chemokines, IL-13, miR-21, proteases (e.g., calpain 14), anti-proteases (e.g., SPINK7) and their related signaling pathways. This work has contributed to the development of new therapeutic strategies and drugs, such as a new class of drugs based on targeting eosinophils (e.g., anti–IL-5 humanized antibodies), which are now FDA approved for clinical usage.

Anti-interleukin 5 Therapy Development

Rothenberg 2016 Cell Anti-IL-5 timeline.


Select Related Publications

Current Projects

  • Role of CDH26 in Th2 immunity
  • Immunosuppressive effects of CDH26-Fc
  • Role of epithelial innate pro-inflammatory cytokines (IL-33 and TSLP)
  • Epithelial cell responses in allergic inflammation
  • Epithelial cell developmental lineages and stem cells in esophagus
  • Isolation of human esophageal epithelial progenitors and role of IL-33
  • RNA-Seq of esophageal cells, including CD3+ T cells, mast cells, eosinophils and epithelial cells
  • Characterization of intraepithelial lymphocytes
  • Characterization of esophageal mast cells and eosinophils
  • Role of NTRK-A and NTRK-A inhibitors in esophageal epithelial cells
  • Role of SPINK proteins and other protease inhibitors in allergic responses

Eosinophilic Gastritis and Colitis

We published the first comprehensive molecular, histopathologic, and clinical characterization of the rare allergic disorder eosinophilic gastritis (EoG) (Caldwell et al. JACI, 2014) and the Eosinophilic Gastritis Diagnostic Panel used to elucidate disease pathogenesis (Shoda et al. JACI, 2020). We further published the first comprehensive molecular characterization of the rare disorder eosinophilic colitis (EoC) (Shoda et al. Gastroenterology, 2022; Research Horizons Science Blog Post). Read More
Cadherin-like 26 in EGID image.

Cadherin-like 26 in EGID - Read More.

Shoda 2020 Graphical Abstract.

Molecular, endoscopic, histologic and circulating biomarker-based diagnosis of eosinophilic gastritis: multi-site study. Click image to expand.

Genome-wide Screening to Identify Representative Biomarkers in Eosinophilic Gastritis.

Genome-wide Screening to Identify Representative Biomarkers in Eosinophilic Gastritis. Click image to expand. 

Tissue-based Molecular Panel in Eosinophilic Gastritis.

Tissue-based Molecular Panel in Eosinophilic Gastritis. Click image to expand. 

Non-invasive Biomarker Research.

Non-invasive Biomarker Research. Click image to expand.